CEO: Raymond Cohen

Advent Contact: Shahzad Malik

Novel sacral neuromodulation system for treating overactive bladder

Axonics has developed a novel and potentially best-in-class implantable sacral neuromodulation (SNM) system for the treatment of overactive bladder and faecal incontinence. It will be the smallest fully implantable, and first rechargeable SNM device, and is expected to work in the body for up to 15 years.

Advent invested in the Series B in 2015.

Axonics® Announces U.S. Food & Drug Administration Approval for its Sacral Neuromodulation System for Urinary Clinical Indications

Axonics® Granted Expanded CE Mark Label; First and Only Sacral Neuromodulation System Approved for Use with Full-Body MRI Scans